The Claim
Higher circulating levels of activin A, ICAM1, MMP7, VEGFA, and eotaxin are associated with poorer performance on the Short Physical Performance Battery (SPPB) and longer 400-meter walk times in older adults aged 70–89 with mobility limitations.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with mobility limitations, higher levels of five specific blood proteins are linked to worse physical performance and slower walking speed.
See the scientific wording
Higher circulating levels of activin A, ICAM1, MMP7, VEGFA, and eotaxin are associated with poorer performance on the Short Physical Performance Battery (SPPB) and longer 400-meter walk times in older adults aged 70–89 with mobility limitations, suggesting these biomarkers may reflect systemic biological aging processes linked to physical function decline.
Aging causes cells to become damaged and stop dividing, but they do not die. These lingering cells release a mix of proteins that trigger inflammation, break down the structural support around muscles and blood vessels, and block new muscle growth. This weakens muscles, reduces blood flow, and slows movement, leading to poorer balance and slower walking.
What the research says
1 studyIn older adults who have trouble walking or moving, higher levels of these five blood proteins are linked to weaker balance, slower walking, and difficulty standing up — meaning these proteins might be signs of the body aging in a way that affects movement.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.